Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Heresco-Levy, U. Articles by Javitt, D. C. Search for Related Content PubMed Citation Articles by Heresco-Levy, U. Articles by Javitt, D. C. Schizophrenia Spectrum Disorders Other Somatic Therapy Other Neuroleptics

Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in Schizophrenia

OBJECTIVE: The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia. METHOD: Twenty-four patients participated in a double-blind, placebo-controlled, 6-week crossover trial with D-cycloserine, 50 mg/day, added to their fixed dose of antipsychotic medication. Clinical ratings were performed every 2 weeks. RESULTS: D-Cycloserine treatment was well tolerated and resulted in a significant reduction in negative symptoms (mean=15%). The degree of improvement did not differ between patients treated with conventional neuroleptics and those treated with olanzapine or risperidone. CONCLUSIONS: These data support the efficacy of the addition of 50 mg/day of D-cycloserine to treatment with conventional neuroleptics and suggest that therapeutic benefits may also be attained when D-cycloserine is added to olanzapine or risperidone.

This article has been cited by other articles:

				G. E. Tsai, H.-Y. Lane, C. M. VanDenBerg, Y.-C. Liu, P. Tsai, and M. W. Jann Disposition of D-Serine in Healthy Adults J. Clin. Pharmacol., April 1, 2008; 48(4): 524 - 527. [Full Text] [PDF]

				C. H. Large Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol, May 1, 2007; 21(3): 283 - 301. [Abstract] [PDF]

				H.-Y. Lane, Y.-C. Chang, Y.-C. Liu, C.-C. Chiu, and G. E. Tsai Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, November 1, 2005; 62(11): 1196 - 1204. [Abstract] [Full Text] [PDF]

				G. G. Kinney, C. Sur, M. Burno, P. J. Mallorga, J. B. Williams, D. J. Figueroa, M. Wittmann, W. Lemaire, and P. J. Conn The Glycine Transporter Type 1 Inhibitor N-[3-(4'-Fluorophenyl)-3-(4'-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior J. Neurosci., August 20, 2003; 23(20): 7586 - 7591. [Abstract] [Full Text] [PDF]

				G. G. Kinney, M. Burno, U. C. Campbell, L. M. Hernandez, D. Rodriguez, L. J. Bristow, and P. J. Conn Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 116 - 123. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us